Description:
Baricitinib, also known as INCB028050 or LY3009104, is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). Baricitinib has been approved by FDA for the treatment of rheumatoid arthritis (RA).
- Molecular Weight:469.41
- Purity:>98%
Molecular Formula:
C16H20N7O6PS
Canonical SMILES:
CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
InChI:
InChI=1S/C16H17N7O2S.H3O4P/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14;1-5(2,3)4/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20);(H3,1,2,3,4)
InChIKey:
FBPOWTFFUBBKBB-UHFFFAOYSA-N
Synonyms:
INCB 028050; LY 3009104; INCB028050; LY3009104; LY-3009104; INCB-028050 More details are to be found
here